Rhythm Pharmaceuticals Stock News & Updates
[WKN: A2H5A0 | Symbol: RYTM]
Doubts About AI Euphoria Overwhelm Rate Cut Effect - Oracle Fuels Concerns About Its AI Investments - DAX with Modest Plus - Recovery in Germany 2026 Likely Weaker Than Expected - Planet Labs Impresses with Strong Growth - Amazon Expands Express Grocery Deliveries
Tech Stocks Plummet – Oracle Fuels AI Doubts The US stock markets , especially the tech-heavy Nasdaq...
Top 5 Biopharma Stocks for the new Health era
Currently, our screening includes 23 biopharma stocks that have risen by at least 10% in the last 20...
5 Rising Biopharma Stocks with over 50% Annual Growth Potential
Dear readers, Last week, I introduced five biopharma stocks that have taken off in recent weeks. It...
Rhythm Pharmaceuticals on the Verge of Approval for its HO drug – Billion-Dollar Market Without Serious Competition
Rhythm Pharmaceuticals is on the verge of the first approval for rare hypothalamic obesity – a billion-dollar...
Rhythm Pharmaceuticals: on the Path to a Pioneer Role in Rare Obesity
Stock fireworks after study data: Rhythm impresses with strong phase-2 results for an oral obesity...
Tech Giants Propel Stock Markets - NVIDIA Reaches a Historic Value of $4 Trillion - Starbucks Sees Interest in its China Business - DAX on Record Hunt: Investors are Fleeing to Europe From US Tariffs - Aehr Test Systems Under Pressure - Plug Power Secures Hydrogen Supply Until 2030
An impressive comeback of technology stocks is boosting global equity markets. Fueled by a strong rise...
Stocks in Action USA: Aehr Test Systems, Plug Power, Rhythm Pharmaceuticals
Aehr Test Systems (AEHR) under pressure: delayed orders and EV market weakness are weighing on the outlook!...
Rhythm Achieves Breakthrough in Rare Obesity – Study Success Fuels Stock Expectations
• Success with IMCIVREE®: Rhythm achieves breakthrough in previously untreatable form of obesity...
Analysts' Top 5 Price Targets of April 8, 2025
Jungheinrich [DE0006219934]: Bernstein reiterates Buy rating and adjusts the price target from €45...
TOP-5 Price Targets by Analysts as of 27.02.25
AppLovin [US03831W1080]: UBS confirms Buy rating with a price target of $630 (88% upside potential) ...
- ‹
- 1
- ›